VERTEX PHARMACEUTICALS INC / MA Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 11 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-05-01: Reporting owner SACHS BRUCE I; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-01: Reporting owner MCGLYNN MARGARET G; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-01: Reporting owner Lee Yuchun; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-05-01: Reporting owner Kearney Terrence C; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-05-01 | SACHS BRUCE I Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,067 6,067 owned after | $217.20 exercise price | $218.20 | 2021-05-04 |
| 2021-05-01 | MCGLYNN MARGARET G Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,034 3,034 owned after | $217.20 exercise price | $218.20 | 2021-05-04 |
| 2021-05-01 | Lee Yuchun Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,067 6,067 owned after | $217.20 exercise price | $218.20 | 2021-05-04 |
| 2021-05-01 | Kearney Terrence C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,067 6,067 owned after | $217.20 exercise price | $218.20 | 2021-05-04 |
| 2021-05-01 | Garber Alan M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,067 6,067 owned after | $217.20 exercise price | $218.20 | 2021-05-04 |
| 2021-04-27 | Sachdev Amit Officer (EVP, Chief Patient Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,884 0 owned after | $86.52 exercise price | $215.53 | 2021-04-29 |
| 2021-03-08 holding as of filing | Liu Joy Officer (SVP, General Counsel) | 3 | Stock Option (Right to buy) Derivative · Direct | Holding | $187.53 exercise price | 2021-03-08 | ||
| 2021-03-08 holding as of filing | Liu Joy Officer (SVP, General Counsel) | 3 | Stock Option (Right to buy) Derivative · Direct | Holding | $155.57 exercise price | 2021-03-08 | ||
| 2021-03-08 holding as of filing | Liu Joy Officer (SVP, General Counsel) | 3 | Stock Option (Right to buy) Derivative · Direct | Holding | $86.52 exercise price | 2021-03-08 | ||
| 2021-02-03 | Parini Michael Officer (EVP, Chief Adm, Leg & BD Off) | 4 | Stock Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −400 1,930 owned after | $86.52 exercise price | $211.00 | 2021-02-05 |
| 2021-02-03 | Arbuckle Stuart A Officer (EVP, Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,554 0 owned after | $86.52 exercise price | $211.00 | 2021-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |